- Home
- EQS vs LTRN Comparison
EQS vs LTRN Comparison
Compare EQS & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQS | LTRN |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 22.2M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EQS | LTRN |
|---|---|---|
| Price | $1.37 | $2.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $1.11 |
| 52 Week High | $2.49 | $5.74 |
Technical Indicators
Market Signals| Indicator | EQS | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 53.14 |
| Support Level | $1.27 | $1.11 |
| Resistance Level | $1.52 | $2.41 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 0.00 | 67.42 |
Price Performance
Historical ComparisonAbout EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.